论文部分内容阅读
目的观察胰激肽原酶片联合黄芪注射液治疗糖尿病肾病的疗效。方法 2009年8月—2012年8月在商丘市第四人民医院肾内科住院治疗的54例糖尿病肾脏病患者被随机分为对照组和治疗组,其中对照组采用常规治疗方法和胰激肽原酶片,治疗组在对照组基础上加用黄芪注射液治疗,3个月后,评价两组的血清肌酐(Scr)、尿素氮(BUN)、血压、尿白蛋白排泄率等改变情况及进行两组临床疗效的比较。结果两组治疗前后尿白蛋白排泄率相比,差异性有统计学意义(P<0.05);治疗组与对照组相比,疗效差异性有统计学意义(P<0.05)。结论胰激肽原酶肠溶片联合黄芪注射液可减少糖尿病肾脏疾病患者的尿白蛋白排出,减轻肾损害,保护肾功能,延缓病变进展。
Objective To observe the effect of pancreatic kallikrein combined with astragalus injection on diabetic nephropathy. Methods From August 2009 to August 2012, 54 patients with diabetic nephropathy hospitalized in Department of Nephrology, Fourth People’s Hospital of Shangqiu City were randomly divided into control group and treatment group. The control group was treated with conventional therapy and pancreatic kallikrein Enzyme tablets and treatment groups were treated with astragalus injection on the basis of the control group. After 3 months, the changes of serum creatinine (Scr), blood urea nitrogen (BUN), blood pressure and urinary albumin excretion rate were evaluated Comparison of clinical efficacy between the two groups. Results There was significant difference in urinary albumin excretion rate between the two groups before and after treatment (P <0.05). There was significant difference in curative effect between the two groups (P <0.05). Conclusion pancreatic kallikrein enteric-coated tablets combined with astragalus injection can reduce urinary albumin excretion, reduce renal damage, protect renal function and delay the progression of disease in patients with diabetic nephropathy.